Sunday, November 8, 2026

USD/CNH Bearish Momentum With A 1% Fall In The Last 10 Sessions

USD/CNH Bearish Momentum With A 1% Fall In The Last 10 Sessions

(VIANEWS) - USD/CNH (USDCNH) has been up by 1.61% for the last 10 sessions. At 04:08 EST on Tuesday, 5 March, USD/CNH (USDCNH) is $7.21.

USD/CNH's yearly highs and lows, it's 0.094% up from its 52-week low and 0.015% down from its 52-week high.

News about

  • According to FXStreet on Monday, 4 March, "Traders also seem reluctant and prefer to wait for more clues about the timing of when the Fed will begin cutting interest rates, which further contributes to capping the upside for the USD/JPY pair. ", "Moreover, oscillators on the daily chart are holding in the positive territory and support prospects for some meaningful upside for the USD/JPY pair. "
  • Usd/jpy: scope for only a moderate move lower in the coming months – rabobank. According to FXStreet on Monday, 4 March, "While we favour an April rate hike over a move in March, we expect USD/JPY to edge lower into the March 19 meeting in anticipation of an early move.", "That said, given the resilience of the US economy and related US inflation risks, we see downside potential in USD/JPY to be limited to a move back to 140.00 on a 12-month view."
  • According to FXStreet on Tuesday, 5 March, "This turns out to be another factor that contributes to the offered tone surrounding the USD/JPY pair, though the downside seems cushioned ahead of the key US macro data and Fed Chair Jerome Powell's congressional testimony. ", "The USD/JPY pair might then surpass the 151.00 mark and accelerate the momentum towards the 151.45 intermediate resistance en route to the 152.00 neighbourhood, or a multi-decade peak set in October 2022 and retested in November 2023."

More news about USD/CNH (USDCNH).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com